Regulatory Approach of Biosimilars

Competitions and/or success in the present pharma industry is determined by the winning patent strategy which mostly pertain to the generic market entry. Generic and branded drug manufacturers both the patent strategy proximally belongs to the Hatch-Waxman Act statutory scheme and ANDA litigations. The Hatch-Waxman Act enacted in 1984 with amendment in 2003 facilitated the entry of generics at an early stage-thereby finishing the battle of branded generic ANDA of blockbuster drugs. All the same the Biologics Price Competition and Innovation (BPCI) Act has maximized the branded-generic patent duel in the biologics realm by imposing a litigated framework on follow-on-biologics. On September 16, 2011 President Obama signed the American Invents Act(AIA) of 2011 indicating a further strategy evolution of patenting branded and generics.

An FDA analysis of drug prices from 1999 to 2004 found that the discount from generic competition was just 6% with one generic competitor, but jumps to 48% with two generic competitors, 56% with three, 61% with four and 67% with five generic producers in a market. Within 2 years of the expiration of the patent of the popular drug Zantac in 1997, generics of Zantac accounted 90% of the treatment’s total sales, and the price for patients was about 10% of its pre-generic price. European patents on biologic treatments began to expire in 2000, and in April 2006, Sandoz and Biopartners successfully received EMEA approval for the first European biogenerics, two products containing human growth hormone.

  • Licensing of biosimilars
  • BLA filing for biosimilars
  • Regulatory prospects of BRIC countries
  • Biowaiver approval for biosimilars

Related Conference of Regulatory Approach of Biosimilars

October 19-20, 2017

9th Annual Congress on Drug Design & Drug Formulation

Seoul, South Korea
October 19-20, 2017

4th International Conference and Exhibition on Pain Medicine

(10 Plenary Forums - 1 Event)
San Francisco, California, USA
October 30-November 01, 2017
A B2B Networking & Global Knowledge Exchange Forum

Annual Congress on Emerging Orphan Drugs and  Rare Diseases

San Antonio, Texas, USA
April 20-21, 2018

4th International Conference on Antibiotics: R&D, B2B

Las Vegas, Nevada, USA
April 26-27, 2018

11th European Biosimilars Congress

Rome, Italy
May 07-09, 2018

15th Annual European Pharma Congress

Frankfurt, Germany
June 18-19, 2018

9th Global Experts Meeting on Neuropharmacology

Paris, France
June 20-22, 2018

7th World Congress on Mass Spectrometry

Rome, Italy
July 09-10, 2018

12th Global
Pharmacovigilance & Clinical Trials Summit

Sydney, Australia
July 16-18, 2018

5th World Congress on Green Chemistry and Green Engineering

Melbourne, Australia
July 16-18, 2018

15th Asia-Pacific Pharma Congress

Melbourne, Australia
Jul 30-Aug 01, 2018

10th World Congress on Pharmacology

Barcelona, Spain
September 13-14, 2018

8th World Congress on Chromatography

Prague, Czech Republic
September 24-26, 2018

7th International Conference on Clinical Trials

Chicago, USA
(10 Plenary Forums - 1 Event)
October 22-23, 2018

18th Annual Pharma Middle East Congress

Abu Dhabi, UAE
November 05-06, 2018

18th Annual Pharmaceutical Chemical Analysis Congress

Madrid, Spain

Regulatory Approach of Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in